AMRX

Amneal Pharmaceuticals, Inc. Class A Common Stock

AMRX
Closed
$16.98
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Country

US

CEO

Mr. Chirag Patel

IPO date

2009

Employees

8,500

ISIN

US03168L1052

Website

amneal.com

Key stats

Open

$17.10

Volume

1.55M

Market cap

$5.44B

Prev. close

$17.02

Impl / hst vl

-

Open interest

$0.00

$16.69

Day’s Range

$17.36

$11.71

52W Range

$17.86

Valuation

38
Valuation score
Overvalued
P/E
44.51
P/S
1.78
P/B
-
Current ratio
2.47
Debt / Equity
-
ROE
-
Gross margin
44.31%
Income growth
77.49%
FCF growth
-157.58

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$17.60
The top 6 analysts forecasts that 12-month price may increase by 3.62%, with a low of $16.16 and a high of $19.95
$16.16
Low
$17.60
Avg
$19.95
High
Current price

Earnings

Q1 ‘26 revenue
$722.52M
Q1 ‘26 net income
$62.26M
Revenue
Net income
Previous EPS
$0.27
Estimate EPS
$0.23
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply